Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Psychedelic policy & regulation stories

Oct 14, 2026

Compass Pathways CEO says company will 'go slow before we go fast' ahead of FDA submission

Compass Pathways CEO Kabir Nath stated the psychedelics company will take a measured approach as it prepares to complete submission of its psychedelic therapy for FDA regulatory review this quarter. The announcement comes as the company joins mental health organizations to mark the first U.S. Treatment-Resistant Depression Awareness Day.

Oct 14, 2026·3 sources
00
Oct 4, 2026

FDA seeks public input on clinical trial design for ibogaine drug products

The U.S. Food and Drug Administration announced a request for information on approaches for designing early-phase clinical trials of ibogaine drug products, marking the first government-funded trials of the psychedelic drug to treat opioid addiction and post-traumatic stress disorder. The agency is seeking public comments, data, and feedback on safety protocols for the studies.

Oct 4, 2026·3 sources
00

FDA advances first government-funded ibogaine clinical trials for opioid addiction and PTSD

U.S. health officials are advancing the first government-funded clinical trials of the psychedelic drug ibogaine to treat opioid addiction and post-traumatic stress disorder. The FDA announced Monday it is seeking public feedback on safety rules for the studies.

Oct 4, 2026·6 sources
00
Sep 18, 2026

Compass Pathways prepares psychedelic drug launch following J&J's ketamine strategy

Compass Pathways executives revealed plans to model their upcoming psychedelic treatment launch after Johnson & Johnson's strategy for Spravato, the ketamine nasal spray, as the FDA considers approval. The move comes as psychedelic therapeutics face a critical juncture following Lykos' failed MDMA therapy approval in 2024.

Sep 18, 2026·2 sources
00
Sep 14, 2026

Definium's LSD-based drug succeeds in third Phase 3 anxiety trial

Definium Therapeutics reported that its oral LSD-based treatment DT120 reduced symptoms of generalized anxiety disorder in a second successful late-stage study, marking the company's third Phase 3 win this year for the candidate.

Sep 14, 2026·2 sources
00
Sep 9, 2026

FDA suggests regulatory flexibility for assessing psychedelic therapies

The FDA indicated openness to innovative approaches for studying psychedelic therapies, including the use of comparators other than placebo, signaling potential regulatory accommodation for this emerging treatment class.

Sep 9, 2026·2 sources
00
Sep 4, 2026

New Zealand approves MDMA for treatment of severe PTSD

New Zealand's pharmaceutical regulator has approved two psychiatrists to prescribe pharmaceutical-grade MDMA to patients suffering from severe post-traumatic stress disorder, marking a significant shift in mental health treatment policy.

Sep 4, 2026·3 sources
00
Aug 12, 2026

Definium reports positive Phase 3 results for single-dose DT120 in generalized anxiety disorder

Definium Therapeutics announced its experimental LSD-based pill significantly reduced anxiety symptoms in a late-stage study, meeting the trial's main goal. The results mark the company's second major win in two months and sent shares up more than 20% in premarket trading.

Aug 12, 2026·2 sources
00
Aug 6, 2026

UK's First Publicly Funded Trial Shows Psilocybin Significantly Improves Treatment-Resistant Depression

A randomized controlled trial conducted through the NHS in England found that a single dose of psilocybin, the active compound in magic mushrooms, produced significant improvements in depression symptoms among 60 adults with treatment-resistant major depressive disorder compared to placebo, with good tolerability.

Aug 6, 2026·4 sources
00
Jun 22, 2026

Definium's LSD-Based Pill Reduces Depression Symptoms in Late-Stage Trial

Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending shares higher. The data brings the drug closer to potential FDA approval.

Jun 22, 2026·2 sources
00
Apr 19, 2026

Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews Including Controversial Ibogaine

President Trump signed an executive order directing the FDA to expedite reviews of psychedelic drugs including ibogaine, which has been embraced by combat veterans but remains controversial. The order was signed alongside podcast host Joe Rogan.

Apr 19, 2026·3 sources
00
Apr 18, 2026

Trump Signs Executive Order to Expedite Psychedelic Drug Review and Reclassification

President Trump signed an executive order directing the FDA to expedite reviews of breakthrough psychedelic therapies for PTSD, depression, and trauma, and to reevaluate their status as controlled substances. The order targets substances including psilocybin.

Apr 18, 2026·3 sources
00

Top claims

  • ▪Compass Pathways expects COMP360 to be subject to an FDA risk evaluation and mitigation strategy (REMS) upon approval and is investing in provider training for drug administration.
  • ▪In Compass Pathways Phase 3 trials, roughly 40% of treatment-resistant depression patients experienced a clinically meaningful response after receiving two doses of COMP360 three weeks apart.
  • ▪The Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.

People involved

Joe RoganDonald Trump

Subtopics

Psychedelic clinical research & trials11Mental Health & Wellbeing8Drug Approval and Clinical Trials5Drug Policy, Pricing & Approval5Stress, Burnout & Well-being5Depression4Psychedelic renaissance4LSD3Psychedelics for PTSD3Trauma & PTSD3Addiction & recovery2Anxiety2Clinical evaluation2Clinical Trial Design & Evaluation2Ibogaine2MDMA2Psilocybin2Psychedelic-assisted therapy2Psychedelics for depression2FDA ibogaine clinical trials1Ketamine1Mental health1Neurodiversity & Cognitive Function1Pharma1

Related timelines

Trump administration

161 stories

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Russia-Ukraine war

136 stories